UCB Ventures Asset Manager Profile - aVenture Research
UCB Ventures is a strategic corporate venture fund of UCB Pharma, focusing on early-stage investments in the US and Europe. The fund targets companies developing novel therapeutics and digital solutions for severe diseases. UCB Ventures makes long-term investments, typically participating in Series A and B rounds, with a commitment to transforming patients' lives through innovative technologies.
The fund's portfolio includes notable companies such as Code Biotherapeutics, Locanabio, and StrideBio. UCB Ventures is known for its speed, agility, and sophisticated approach to investing. With offices in Brussels, London, and Boston, the fund offers strategic support and works closely with entrepreneurs to maximize the potential of their ventures in the biopharmaceutical and digital health sectors.
Portfolio Snapshot
Observed round participation, including acquisitions and grants. Current holdings, investor exits, and write-offs are not established.
67Holding And Other Investment OfficesEdition: 1987
679Miscellaneous InvestingEdition: 1987
6799Investors, Not Elsewhere ClassifiedEdition: 1987
Industry
Venture Capital Firms
Investment Management Companies
Investment Companies
Financial Services Companies
Private Equity Firms
Show 6 more industry codes
NAICS
523910Miscellaneous IntermediationEdition: 2022
523940Portfolio Management and Investment AdviceEdition: 2022
525Funds, Trusts, and Other Financial VehiclesEdition: 2022
SIC
60Depository InstitutionsEdition: 1987
UCB Ventures
UCB Ventures, UCB Pharma's strategic fund, invests in early-stage US and European companies innovating in therapeutics and digital solutions for severe diseases.
8
Operating
2017
City of Brussels, Brussels-Capital Region, BE🇧🇪Belgium